Rapport Therapeutics (NASDAQ:RAPP) Upgraded to Hold at Wall Street Zen

Rapport Therapeutics (NASDAQ:RAPP) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Sunday.

A number of other research analysts also recently weighed in on the stock. Citizens Jmp raised their price target on shares of Rapport Therapeutics from $77.00 to $80.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Thursday. Wells Fargo & Company set a $51.00 target price on shares of Rapport Therapeutics in a research note on Friday, December 19th. HC Wainwright lifted their price objective on Rapport Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Finally, Citigroup reiterated a “market outperform” rating on shares of Rapport Therapeutics in a research report on Thursday, January 8th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Rapport Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $48.33.

Rapport Therapeutics Price Performance

RAPP opened at $26.93 on Friday. The stock has a market capitalization of $1.28 billion, a PE ratio of -9.94 and a beta of 1.63. Rapport Therapeutics has a 12-month low of $6.43 and a 12-month high of $42.27. The firm’s fifty day moving average price is $28.59 and its 200 day moving average price is $23.78.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.06. On average, equities research analysts forecast that Rapport Therapeutics will post -3.65 earnings per share for the current fiscal year.

Insider Activity at Rapport Therapeutics

In other Rapport Therapeutics news, CEO Abraham Ceesay sold 5,083 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $26.11, for a total transaction of $132,717.13. Following the completion of the sale, the chief executive officer owned 25,812 shares of the company’s stock, valued at approximately $673,951.32. This represents a 16.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Krishnaswamy Yeleswaram sold 2,840 shares of Rapport Therapeutics stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $30.05, for a total transaction of $85,342.00. Following the completion of the sale, the insider owned 296,991 shares of the company’s stock, valued at $8,924,579.55. This represents a 0.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 67,655 shares of company stock worth $1,863,705 over the last three months. Company insiders own 13.57% of the company’s stock.

Institutional Trading of Rapport Therapeutics

Large investors have recently modified their holdings of the business. Russell Investments Group Ltd. purchased a new position in shares of Rapport Therapeutics in the third quarter worth about $43,000. Strs Ohio raised its holdings in shares of Rapport Therapeutics by 23.5% during the third quarter. Strs Ohio now owns 2,100 shares of the company’s stock valued at $62,000 after purchasing an additional 400 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Rapport Therapeutics in the 3rd quarter worth approximately $143,000. Sandia Investment Management LP purchased a new stake in Rapport Therapeutics in the 3rd quarter worth approximately $178,000. Finally, SG Americas Securities LLC bought a new stake in Rapport Therapeutics during the 3rd quarter valued at approximately $186,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.